NZ616264A - Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone - Google Patents

Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone

Info

Publication number
NZ616264A
NZ616264A NZ616264A NZ61626408A NZ616264A NZ 616264 A NZ616264 A NZ 616264A NZ 616264 A NZ616264 A NZ 616264A NZ 61626408 A NZ61626408 A NZ 61626408A NZ 616264 A NZ616264 A NZ 616264A
Authority
NZ
New Zealand
Prior art keywords
naltrexone
buprenorphine
analgesia
relating
medicinal compositions
Prior art date
Application number
NZ616264A
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0703966A external-priority patent/GB2447014A/en
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of NZ616264A publication Critical patent/NZ616264A/en

Links

Abstract

Disclosed herein is an analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.
NZ616264A 2007-03-01 2008-02-15 Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone NZ616264A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703966A GB2447014A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
NZ59925208 2008-02-15

Publications (1)

Publication Number Publication Date
NZ616264A true NZ616264A (en) 2014-10-31

Family

ID=51796560

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ616264A NZ616264A (en) 2007-03-01 2008-02-15 Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone

Country Status (1)

Country Link
NZ (1) NZ616264A (en)

Similar Documents

Publication Publication Date Title
HK1139871A1 (en) Improvements in and relating to medicinal compositions
MX2009009132A (en) Improved medicinal compositions comprising buprenorphine and naltrexone.
JP2010520186A5 (en)
MX2009009133A (en) Improved medicinal compositions comprising buprenorphine and naloxone.
JP2010520183A5 (en)
MX2009009134A (en) Improved medicinal compositions comprising buprenorphine and nalmefene.
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2007134292A3 (en) Treprostinil administration using a metered dose inhaler
MX2009002314A (en) Pharmaceutical compositions comprising hgh for oral delivery.
HUP0203588A2 (en) Analgesic pharmaceutical compositions and their use
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
IL196425A (en) Oral unit dose form containing ibuprofen and famotidine
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
JP2010520185A5 (en)
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
WO2008106689A3 (en) Breakthrough pain management
JP2010520184A5 (en)
NZ590981A (en) Transdermal therapeutic system (TTS) for administration with a wafer
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 4 YEARS UNTIL 15 FEB 2016 BY AJ PARK

Effective date: 20150316

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 FEB 2017 BY COMPUTER PACKAGES INC

Effective date: 20160119

LAPS Patent lapsed